Fibrocell Science (FCSC) 10-Q 8 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	1-May-15
Document And Entity Information [Abstract]
Entity Registrant Name	Fibrocell Science, Inc.
Entity Central Index Key	357097
Current Fiscal Year End Date	-19
Entity Filer Category	Accelerated Filer
Trading Symbol	fcsc
Document Type	10-Q
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Amendment Flag	FALSE
Entity Common Stock, Shares Outstanding		40,888,065
Entity Current Reporting Status	Yes

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$33,301	$37,495
Accounts receivable, net of allowance for doubtful accounts of $17 and $17, respectively	3	4
Inventory	544	571
Prepaid expenses and other current assets	1,078	1,279
Total current assets	34,926	39,349
Property and equipment, net of accumulated depreciation of $1,053 and $1,051, respectively	1,704	1,598
Intangible assets, net of accumulated amortization of $1,791 and $1,653, respectively	4,549	4,687
Total assets	41,179	45,634
Current liabilities:
Accounts payable	1,898	1,124
Accrued expenses	2,697	1,675
Deferred revenue	588	416
Warrant liability, current	851	278
Total current liabilities	6,034	3,493
Warrant liability, long term	12,098	11,008
Other long term liabilities	771	724
Total liabilities	18,903	15,225
Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares outstanding	0	0
Common stock, $0.001 par value; 100,000,000 shares authorized; 40,888,065 and 40,856,815 shares issued and outstanding, respectively	41	41
Additional paid-in capital	143,478	143,086
Accumulated deficit	-121,243	-112,718
Total stockholders’ equity	22,276	30,409
Total liabilities and stockholders’ equity	$41,179	$45,634

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, except Share data, unless otherwise specified
Statement of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts (in dollars)	$17	$17
Property and equipment, accumulated depreciation (in dollars)	1,053	1,051
Intangible assets, accumulated amortization (in dollars)	$1,791	$1,653
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	40,888,065	40,856,815
Common stock, shares outstanding	40,888,065	40,856,815

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Income Statement [Abstract]
Product sales	$113	$46
Collaboration revenue	81	0
Total revenues	194	46
Cost of revenues	147	793
Gross profit (loss)	47	-747
Research and development expense	3,987	7,915
Selling, general and administrative expense	2,924	2,338
Operating loss	-6,864	-11,000
Other income (expense):
Warrant revaluation and other finance expense	-1,663	-3,050
Other income	0	40
Interest income	2	1
Loss before income taxes	-8,525	-14,009
Net loss	($8,525)	($14,009)
Per Share Information:
Basic and diluted	($0.21)	($0.35)
Weighted average number of common shares outstanding
Basic and diluted	40,861,329	40,583,591

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (USD $)	Total	Common Stock	Additional paid-in capital	Accumulated deficit
In Thousands, except Share data
Balance at Dec. 31, 2014	$30,409	$41	$143,086	($112,718)
Balance (shares) at Dec. 31, 2014	40,856,815	40,856,815
Stock-based compensation expense	240		240
Exercise of stock options (shares)	31,250	31,250
Exercise of stock options	152		152
Net loss	-8,525			-8,525
Balance at Mar. 31, 2015	$22,276	$41	$143,478	($121,243)
Balance (shares) at Mar. 31, 2015	40,888,065	40,888,065

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities:
Net loss	($8,525)	($14,009)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	240	303
Stock issued for supplemental stock issuance agreement	0	5,154
Warrant revaluation and other finance expense	1,663	3,050
Depreciation and amortization	140	222
Provision for doubtful accounts	0	5
Change in operating assets and liabilities:
Accounts receivable	1	-35
Inventory	27	91
Prepaid expenses and other current assets	201	317
Other assets	0	72
Accounts payable	774	-2,055
Accrued expenses and other long-term liabilities	1,069	931
Deferred revenue	172	1
Net cash used in operating activities	-4,238	-5,953
Cash flows from investing activities:
Purchase of property and equipment	-108	-79
Net cash used in investing activities	-108	-79
Cash flows from financing activities:
Proceeds from the issuance of common stock	152	0
Net cash provided by financing activities	152	0
Net decrease in cash and cash equivalents	-4,194	-6,032
Cash and cash equivalents, beginning of period	37,495	60,033
Cash and cash equivalents, end of period	$33,301	$54,001

Business_and_Organization

Business and Organization	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business and Organization	Business and Organization
	Fibrocell Science, Inc. (as used herein, “we,” “us,” “our,” “Fibrocell” or the “Company”) is the parent company of Fibrocell Technologies, Inc. (“Fibrocell Tech”) and Fibrocell Science Hong Kong Limited (“Fibrocell Hong Kong”), a company organized under the laws of Hong Kong. Fibrocell Tech is the parent company of Isolagen Europe Limited, a company organized under the laws of the United Kingdom (“Isolagen Europe”), Isolagen Australia Pty Limited, a company organized under the laws of Australia (“Isolagen Australia”), and Isolagen International, S.A., a company organized under the laws of Switzerland (“Isolagen Switzerland”). The Company’s international activities are currently immaterial.
	Fibrocell is an autologous cell and gene therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs.  Our most advanced drug candidate, azficel-T, uses the Company's Food and Drug Administration ("FDA") approved proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of chronic dysphonia resulting from vocal cord scarring or atrophy.  In collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology, Fibrocell is also developing gene therapies for orphan skin diseases using gene-modified autologous fibroblasts.  The Company’s lead orphan gene-therapy drug candidate, FCX-007, is in late stage pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa ("RDEB").  Fibrocell is also in pre-clinical development of FCX-013, a second gene-therapy drug candidate, for the treatment of linear scleroderma.

Basis_of_Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2015
Basis of Presentation
Basis of Presentation	Basis of Presentation
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnote disclosures required by GAAP for complete consolidated financial statements.  In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included.  These financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014, filed with the Securities and Exchange Commission (“SEC”). The results of the Company’s operations for any interim period are not necessarily indicative of the results of operations for any other interim period or full year.
	There have been certain reclassifications made to the prior year’s results of operations to conform to the current year’s presentation. Compensation and related expenses for manufacturing and facilities personnel of $0.5 million were reclassed from selling, general and administrative expense to research and development expense for the three months ended March 31, 2014.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the consolidated financial statements and notes.  In addition, management’s assessment of the Company’s ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows.  Actual results may differ materially from those estimates.
	Revenue Recognition
	Product Sales. The FDA approved the Company's Biologics License Application ("BLA") in June of 2011 for the aesthetic indication of azficel-T, commercial name LAVIV®. The Company recognizes revenue over the period LAVIV® is shipped for injection in accordance with Accounting Standards Codification ("ASC") 605 Revenue Recognition (“ASC 605”).  In general, ASC 605 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists, (2) delivery has occurred or services rendered, (3) the fee is fixed and determinable and (4) collectability is reasonably assured.  One full course of LAVIV® therapy includes three series of injections. Corresponding revenue is recognized on a prorata basis as each of the three series of injections is shipped to the physician. The Company no longer actively promotes this product.
	Note 3. Summary of Significant Accounting Policies (continued)
	Collaboration Revenue. The Company's collaboration agreements may contain multiple elements, such as fees to perform proof of concept studies, product development, aid in obtaining U.S. patents and trademarks, and royalties based upon future commercial sales. The deliverables under such an arrangement are evaluated under ASC 605-25, Revenue Recognition: Multiple-Element Arrangements. Each required deliverable is evaluated to determine whether it qualifies as a separate unit of accounting based on whether the deliverable has “stand-alone value” to the customer. The arrangement’s consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. In general, the consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables. Collaboration revenue is recognized on a gross basis, in accordance with the criteria set forth in ASC 605-45, Revenue Recognition: Principal Agent Considerations. Collaboration revenue for the quarter ended March 31, 2015 is related to a research and development agreement that the Company has with an unrelated third party to investigate potential new non-pharmaceutical applications for the Company's conditioned fibroblast media technology. Revenue recognized from this collaboration relates to an upfront license fee and a proof of concept study currently underway.
	Cost of Revenues
	Cost of revenues includes expenses related to product sales and collaboration revenue.
	Costs Related to Product Sales. Costs include the processing of cells for LAVIV®, including direct and indirect costs. Cost of product sales is accounted for using a standard cost system which allocates the direct costs associated with the Company’s manufacturing, facility, quality control, and quality assurance operations as well as overhead costs.
	Costs Related to Collaboration Revenue. Costs directly related to deliverables in a revenue-generating collaboration are charged to cost of revenues as incurred.
	Income Taxes
	In accordance with ASC 270, Interim Reporting and ASC 740, Income Taxes, the Company is required at the end of each interim period to determine the best estimate of its annual effective tax rate and then apply that rate in providing for income taxes on a current year-to-date (interim period) basis.  For the three months ended March 31, 2015 and 2014, the Company recorded no tax expense or benefit due to the expected current year loss and its historical losses.  The Company had not recorded its net deferred tax asset as of either March 31, 2015 or December 31, 2014, because it maintains a full valuation against all deferred tax assets as management has determined that it is not more likely than not that the Company will realize these future tax benefits. For each of the three months ended March 31, 2015 and 2014, the Company had no uncertain tax positions.
	Loss Per Share Data
	Basic loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during a period.  The diluted loss per share calculation gives effect to dilutive options, warrants, convertible notes, convertible preferred stock, and other potential dilutive common stock including selected restricted shares of common stock outstanding during the period.  Diluted loss per share is based on the treasury stock method and includes the effect from potential issuance of common stock, such as shares issuable pursuant to the exercise of stock options and warrants, assuming the exercise of all in-the-money stock options and warrants.  Common share equivalents have been excluded where their inclusion would be anti-dilutive.
	For all periods present, diluted net loss per common share was the same as basic net loss per common share as the effects of the Company’s potential common stock equivalents were antidilutive. Total antidilutive securities were 8,918,550 and 8,306,770 at March 31, 2015 and 2014, respectively, and consisted of stock options and warrants.
	Note 3. Summary of Significant Accounting Policies (continued)
	Recently Issued Accounting Pronouncements
	There have been no recently issued accounting pronouncements that the Company believes will have a material impact on its consolidated results of operations, cash flows or financial position upon adoption that have not been previously disclosed.
	Subsequent Events
	The Company evaluates all subsequent events, through the date the consolidated financial statements are issued, to determine if there are any events that require disclosure.  No such events have been identified through the date of this filing.

Inventory

Inventory	3 Months Ended
	Mar. 31, 2015
Inventory Disclosure [Abstract]
Inventory	Inventory
	Inventories, which were solely related to LAVIV®, consisted of the following as of:
		($ in thousands)	31-Mar-15		31-Dec-14
		Raw materials	$	355	$	357
		Work in process	189		214
		Inventory	$	544	$	571

Warrants

Warrants	3 Months Ended
	Mar. 31, 2015
Warrants [Abstract]
Warrants	Warrants
	The Company accounts for stock warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreement.  Stock warrants are accounted for as a derivative in accordance with ASC 815, Derivatives and Hedging (“ASC 815”) if the stock warrants contain “down-round protection” or other terms that could potentially require “net cash settlement” and therefore, do not meet the scope exception for treatment as an equity instrument.  Since “down-round protection” is not an input into the calculation of the fair value of the warrants, the warrants cannot be considered indexed to the Company’s own stock which is a requirement for the scope exception as outlined under ASC 815.  Warrant instruments that could potentially require “net cash settlement” in the absence of express language precluding such settlement or those which include “down-round provisions” are initially classified as derivative liabilities at their estimated fair values, regardless of the likelihood that such instruments will ever be settled in cash.  The Company will continue to classify the fair value of the warrants that contain “down-round protection” or “net cash settlement” as a liability until the warrants are exercised, expire or are amended in a way that would no longer require these warrants to be classified as a liability.
	The following table summarizes outstanding liability-classified warrants to purchase common stock as of:
		Number of Warrants
	Liability-classified warrants	March 31, 2015			December 31, 2014			Exercise		Expiration
								Price		Dates
	Issued in Series A, B and D Preferred Stock offerings	2,247,118			2,247,118			$	6.25	Oct 2015 - Dec 2016
	Issued in March 2010 financing	393,416			393,416			$	6.25	Mar-16
	Issued in June 2011 financing	6,113			6,113			$	22.5	Jun-16
	Issued in August 2011 financing	565,759			565,759			$	18.75	Aug-16
	Issued to placement agents in August 2011 financing	50,123			50,123			$	13.635	Aug-16
	Issued in Series B, D and E Preferred Stock offerings	76,120			76,120			$	2.5	Nov 2015 - Dec 2017
	Issued with Convertible Notes	1,125,578			1,125,578			$	2.5	Jun-18
	Issued in Series E Preferred Stock offering	1,568,823			1,568,823			$	7.5	Dec-18
	Total	6,033,050			6,033,050
	There were no warrants exercised or canceled during the three months ended March 31, 2015.
	Liability-classified Warrants
	The foregoing warrants were recorded as derivative liabilities at their estimated fair value at the date of issuance, with the subsequent changes in estimated fair value recorded in other income (expense) in the Company’s consolidated statement of operations in each subsequent period.  The change in the estimated fair value of the Company's warrant liability for the three months ended March 31, 2015 and 2014 resulted in non-cash expense of approximately $1.7 million and $3.1 million, respectively. The Company utilizes the Monte Carlo simulation valuation method to value its liability-classified warrants.
	The estimated fair value of these warrants is determined using Level 3 inputs.  Inherent in the Monte Carlo valuation model are assumptions related to expected stock-price volatility, expected life, risk-free interest rate and dividend yield.  The Company estimates the volatility of its common stock based on historical volatility that matches the expected remaining life of the warrants.  The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the warrants.  The expected life of the warrants is assumed to be equivalent to their remaining contractual term.  The dividend rate is based on the historical rate, which the Company anticipates will remain at zero.
	The following table summarizes the calculated aggregate fair values, along with the assumptions utilized in each calculation:
	($ in thousands)	March 31, 2015				December 31, 2014
	Calculated aggregate value	$	12,949			$	11,286
	Weighted average exercise price per share	$	7.08			$	7.08
	Closing price per share of common stock	$	4.51			$	2.59
	Volatility	78.5		%		67.6		%
	Weighted average remaining expected life	2 years, 4 months				2 years, 7 months
	Risk-free interest rate	0.63		%		0.86		%
	Dividend yield	—				—

Fair_Value_Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements
	Assets and Liabilities Measured at Fair Value on a Recurring Basis
	The Company adopted the accounting guidance on fair value measurements for financial assets and liabilities measured on a recurring basis. The guidance requires fair value measurements be classified and disclosed in one of the following three categories:
	•Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.
	•Level 2: Quoted prices in markets that are not active or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability.
	•Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).
	The following fair value hierarchy table presents information about each major category of the Company’s financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2015 and December 31, 2014:
	Note 6. Fair Value Measurements (continued)
		Fair value measurement using
	($ in thousands)	Quoted prices in		Significant		Significant		Total
		active markets (Level 1)		other		unobservable
				observable		inputs
				inputs (Level 2)		(Level 3)
	Balance at March 31, 2015
	Assets:
	Cash and cash equivalents	$	33,301	$	—	$	—	$	33,301
	Liabilities:
	Warrant liability	$	—	$	—	$	12,949	$	12,949
		Fair value measurement using
	($ in thousands)	Quoted prices in		Significant		Significant		Total
		active markets (Level 1)		other		unobservable
				observable		inputs
				inputs (Level 2)		(Level 3)
	Balance at December 31, 2014
	Assets:
	Cash and cash equivalents	$	37,495	$	—	$	—	$	37,495
	Liabilities:
	Warrant liability	$	—	$	—	$	11,286	$	11,286
	The reconciliation of the warrant liability measured at fair value on a recurring basis using unobservable inputs (Level 3) was as follows:
		Warrant
	($ in thousands)	Liability
	Balance at December 31, 2014	$	11,286
	Exercise of warrants	—
	Change in fair value of warrant liability	1,663
	Balance at March 31, 2015	$	12,949
	The fair value of the warrant liability is based on Level 3 inputs. For this liability, the Company developed its own assumptions that do not have observable inputs or available market data to support the fair value.  See Note 5 for further discussion of the warrant liability.  The Company believes that the fair values of the Company’s current assets and current liabilities approximate their reported carrying amounts. There were no transfers between Level 1, 2 and 3 during the periods presented.

ShareBased_Compensation

Share-Based Compensation	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-Based Compensation	Share-Based Compensation
	The Company’s board of directors (the “Board”) adopted the 2009 Equity Incentive Plan (as amended to date, the “Plan”) effective September 3, 2009.  The Plan is intended to further align the interests of the Company and its stockholders with its employees, including its officers, non-employee directors, consultants and advisers by providing incentives for such persons to exert maximum efforts for the success of the Company.  The Plan allows for the issuance of up to 5,600,000 shares of the Company’s common stock.  The Company issued 206,000 options outside of the Plan to consultants.
	The types of awards that may be granted under the Plan include stock options (both non-qualified stock options and incentive stock options), stock appreciation rights, stock awards, stock units and other stock-based awards.  The term of each award is determined by the Compensation Committee of the Board of Directors at the time each award is granted, provided that the terms of options do not exceed ten years.  Vesting schedules for the stock options vary, but generally vest 25% per year, over four years.  The Plan had 2,700,253 options available for grant as of March 31, 2015.
	Note 7. Share-Based Compensation (continued)
	Total share-based compensation expense recognized using the straight-line attribution method in the consolidated statements of operations is as follows:
		Three months ended March 31,
	($ in thousands)	2015			2014
	Stock option compensation expense for employees and directors	$	240		$	300
	Equity awards for non-employees issued for services	—			3
	Total stock-based compensation expense	$	240		$	303
	($ in thousands except share and per share data)	Number of		Weighted-			Weighted-average	Aggregate
		shares		average			remaining	intrinsic
				exercise			contractual	value ($ in thousands)
				price			term (in
							years)
	Outstanding at December 31, 2014	2,086,450		$	7.43		8 years	$	—
	Granted	830,300		4.13
	Exercised	(31,250	)	4.86
	Forfeited	—		—
	Expired	—		—
	Outstanding at March 31, 2015	2,885,500		$	6.51		8 years, 4 months	$	1,510
	Exercisable at March 31, 2015	1,162,250		$	10.25		7 years, 3 months	$	349
	The total fair value of shares vested during the three months ended March 31, 2015 was approximately $0.2 million.  As of March 31, 2015, there was approximately $4.1 million of total unrecognized compensation cost, related to time-based and performance-based non-vested stock options.  That cost is expected to be recognized over a weighted-average period of 3.26 years.  As of March 31, 2015, there was no unrecognized compensation expense related to non-vested non-employee options.
	During the three months ended March 31, 2015 and 2014, the weighted average fair market value of the options granted was $3.39 and $2.88, respectively.  The fair market value of these options was computed using the Black-Scholes option-pricing model with the following key weighted average assumptions for the three months ended as of the dates indicated:
		March 31, 2015		March 31, 2014
	Expected life	6 years, 2 months		6 years, 3 months
	Interest rate	1.48	%	1.99	%
	Dividend yield	—		—
	Volatility	106.3	%	71	%
	The Company uses a peer group to determine historical stock price volatility as it has not had enough standalone trading to satisfy the "look-back" requirements of ASC 718, Compensation: Stock Compensation. For grants issued during the first quarter of 2015, the Company reassessed those companies it would include in its peer group, resulting in an increase in volatility as compared to the first quarter of 2014.

Collaboration_Agreements

Collaboration Agreements	3 Months Ended
	Mar. 31, 2015
Collaboration Agreements
Collaboration Agreements	Collaboration Agreement with Related Party
	Intrexon is an affiliate of the Company’s largest shareholder, NRM VII Holdings I, LLC.  In addition, two of the Company’s seven directors are also affiliates of NRM VII Holdings I, LLC.
	Note 8. Collaboration Agreement with Related Party (continued)
	For the three months ended March 31, 2015 and 2014, the Company incurred expenses of $1.7 million and $1.1 million, respectively, for work performed under the Company's exclusive channel collaboration agreement, as amended, with Intrexon. As of March 31, 2015 and December 31, 2014, the Company had outstanding payables to Intrexon of $1.9 million and $1.0 million, respectively.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the consolidated financial statements and notes.  In addition, management’s assessment of the Company’s ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows.  Actual results may differ materially from those estimates.
Revenue Recognition	Revenue Recognition
	Product Sales. The FDA approved the Company's Biologics License Application ("BLA") in June of 2011 for the aesthetic indication of azficel-T, commercial name LAVIV®. The Company recognizes revenue over the period LAVIV® is shipped for injection in accordance with Accounting Standards Codification ("ASC") 605 Revenue Recognition (“ASC 605”).  In general, ASC 605 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists, (2) delivery has occurred or services rendered, (3) the fee is fixed and determinable and (4) collectability is reasonably assured.  One full course of LAVIV® therapy includes three series of injections. Corresponding revenue is recognized on a prorata basis as each of the three series of injections is shipped to the physician. The Company no longer actively promotes this product.
	Note 3. Summary of Significant Accounting Policies (continued)
	Collaboration Revenue. The Company's collaboration agreements may contain multiple elements, such as fees to perform proof of concept studies, product development, aid in obtaining U.S. patents and trademarks, and royalties based upon future commercial sales. The deliverables under such an arrangement are evaluated under ASC 605-25, Revenue Recognition: Multiple-Element Arrangements. Each required deliverable is evaluated to determine whether it qualifies as a separate unit of accounting based on whether the deliverable has “stand-alone value” to the customer. The arrangement’s consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. In general, the consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables. Collaboration revenue is recognized on a gross basis, in accordance with the criteria set forth in ASC 605-45, Revenue Recognition: Principal Agent Considerations. Collaboration revenue for the quarter ended March 31, 2015 is related to a research and development agreement that the Company has with an unrelated third party to investigate potential new non-pharmaceutical applications for the Company's conditioned fibroblast media technology. Revenue recognized from this collaboration relates to an upfront license fee and a proof of concept study currently underway.
	Cost of Revenues
	Cost of revenues includes expenses related to product sales and collaboration revenue.
	Costs Related to Product Sales. Costs include the processing of cells for LAVIV®, including direct and indirect costs. Cost of product sales is accounted for using a standard cost system which allocates the direct costs associated with the Company’s manufacturing, facility, quality control, and quality assurance operations as well as overhead costs.
	Costs Related to Collaboration Revenue. Costs directly related to deliverables in a revenue-generating collaboration are charged to cost of revenues as incurred.
Income Taxes	Income Taxes
	In accordance with ASC 270, Interim Reporting and ASC 740, Income Taxes, the Company is required at the end of each interim period to determine the best estimate of its annual effective tax rate and then apply that rate in providing for income taxes on a current year-to-date (interim period) basis.  For the three months ended March 31, 2015 and 2014, the Company recorded no tax expense or benefit due to the expected current year loss and its historical losses.  The Company had not recorded its net deferred tax asset as of either March 31, 2015 or December 31, 2014, because it maintains a full valuation against all deferred tax assets as management has determined that it is not more likely than not that the Company will realize these future tax benefits.
Loss Per Share Data	Loss Per Share Data
	Basic loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during a period.  The diluted loss per share calculation gives effect to dilutive options, warrants, convertible notes, convertible preferred stock, and other potential dilutive common stock including selected restricted shares of common stock outstanding during the period.  Diluted loss per share is based on the treasury stock method and includes the effect from potential issuance of common stock, such as shares issuable pursuant to the exercise of stock options and warrants, assuming the exercise of all in-the-money stock options and warrants.  Common share equivalents have been excluded where their inclusion would be anti-dilutive.
	For all periods present, diluted net loss per common share was the same as basic net loss per common share as the effects of the Company’s potential common stock equivalents were antidilutive.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements
	There have been no recently issued accounting pronouncements that the Company believes will have a material impact on its consolidated results of operations, cash flows or financial position upon adoption that have not been previously disclosed.
Subsequent Events	Subsequent Events
	The Company evaluates all subsequent events, through the date the consolidated financial statements are issued, to determine if there are any events that require disclosure.  No such events have been identified through the date of this filing.

Inventory_Tables

Inventory (Tables)	3 Months Ended
	Mar. 31, 2015
Inventory Disclosure [Abstract]
Inventories	Inventories, which were solely related to LAVIV®, consisted of the following as of:
		($ in thousands)	31-Mar-15		31-Dec-14
		Raw materials	$	355	$	357
		Work in process	189		214
		Inventory	$	544	$	571

Warrants_Tables

Warrants (Tables)	3 Months Ended
	Mar. 31, 2015
Warrants [Abstract]
Outstanding Warrants to Purchase Common Stock	The following table summarizes outstanding liability-classified warrants to purchase common stock as of:
		Number of Warrants
	Liability-classified warrants	March 31, 2015			December 31, 2014			Exercise		Expiration
								Price		Dates
	Issued in Series A, B and D Preferred Stock offerings	2,247,118			2,247,118			$	6.25	Oct 2015 - Dec 2016
	Issued in March 2010 financing	393,416			393,416			$	6.25	Mar-16
	Issued in June 2011 financing	6,113			6,113			$	22.5	Jun-16
	Issued in August 2011 financing	565,759			565,759			$	18.75	Aug-16
	Issued to placement agents in August 2011 financing	50,123			50,123			$	13.635	Aug-16
	Issued in Series B, D and E Preferred Stock offerings	76,120			76,120			$	2.5	Nov 2015 - Dec 2017
	Issued with Convertible Notes	1,125,578			1,125,578			$	2.5	Jun-18
	Issued in Series E Preferred Stock offering	1,568,823			1,568,823			$	7.5	Dec-18
	Total	6,033,050			6,033,050
Summary of other assumptions used by entity	The following table summarizes the calculated aggregate fair values, along with the assumptions utilized in each calculation:
	($ in thousands)	March 31, 2015				December 31, 2014
	Calculated aggregate value	$	12,949			$	11,286
	Weighted average exercise price per share	$	7.08			$	7.08
	Closing price per share of common stock	$	4.51			$	2.59
	Volatility	78.5		%		67.6		%
	Weighted average remaining expected life	2 years, 4 months				2 years, 7 months
	Risk-free interest rate	0.63		%		0.86		%
	Dividend yield	—				—

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]	The following table summarizes the calculated aggregate fair values, along with the assumptions utilized in each calculation:
	($ in thousands)	March 31, 2015			December 31, 2014
	Calculated aggregate value	$	12,949		$	11,286
	Weighted average exercise price per share	$	7.08		$	7.08
	Closing price per share of common stock	$	4.51		$	2.59
	Volatility	78.5		%	67.6		%
	Weighted average remaining expected life	2 years, 4 months			2 years, 7 months
	Risk-free interest rate	0.63		%	0.86		%
	Dividend yield	—			—
Company's Financial Assets and Liability Measured at Fair Value on a Recurring Basis	The following fair value hierarchy table presents information about each major category of the Company’s financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2015 and December 31, 2014:
	Note 6. Fair Value Measurements (continued)
		Fair value measurement using
	($ in thousands)	Quoted prices in			Significant			Significant		Total
		active markets (Level 1)			other			unobservable
					observable			inputs
					inputs (Level 2)			(Level 3)
	Balance at March 31, 2015
	Assets:
	Cash and cash equivalents	$	33,301		$	—		$	—	$	33,301
	Liabilities:
	Warrant liability	$	—		$	—		$	12,949	$	12,949
		Fair value measurement using
	($ in thousands)	Quoted prices in			Significant			Significant		Total
		active markets (Level 1)			other			unobservable
					observable			inputs
					inputs (Level 2)			(Level 3)
	Balance at December 31, 2014
	Assets:
	Cash and cash equivalents	$	37,495		$	—		$	—	$	37,495
	Liabilities:
	Warrant liability	$	—		$	—		$	11,286	$	11,286
Reconciliation of Warrant Liability Measured at Fair Value on Recurring Basis	The reconciliation of the warrant liability measured at fair value on a recurring basis using unobservable inputs (Level 3) was as follows:
		Warrant
	($ in thousands)	Liability
	Balance at December 31, 2014	$	11,286
	Exercise of warrants	—
	Change in fair value of warrant liability	1,663
	Balance at March 31, 2015	$	12,949

ShareBased_Compensation_Tables

Share-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Share-Based Compensation Expense	Total share-based compensation expense recognized using the straight-line attribution method in the consolidated statements of operations is as follows:
		Three months ended March 31,
	($ in thousands)	2015			2014
	Stock option compensation expense for employees and directors	$	240		$	300
	Equity awards for non-employees issued for services	—			3
	Total stock-based compensation expense	$	240		$	303
Summary of Stock Option Activity
	($ in thousands except share and per share data)	Number of		Weighted-			Weighted-average	Aggregate
		shares		average			remaining	intrinsic
				exercise			contractual	value ($ in thousands)
				price			term (in
							years)
	Outstanding at December 31, 2014	2,086,450		$	7.43		8 years	$	—
	Granted	830,300		4.13
	Exercised	(31,250	)	4.86
	Forfeited	—		—
	Expired	—		—
	Outstanding at March 31, 2015	2,885,500		$	6.51		8 years, 4 months	$	1,510
	Exercisable at March 31, 2015	1,162,250		$	10.25		7 years, 3 months	$	349
Details of Fair Value Option Award	The fair market value of these options was computed using the Black-Scholes option-pricing model with the following key weighted average assumptions for the three months ended as of the dates indicated:
		March 31, 2015		March 31, 2014
	Expected life	6 years, 2 months		6 years, 3 months
	Interest rate	1.48	%	1.99	%
	Dividend yield	—		—
	Volatility	106.3	%	71	%

Basis_of_Presentation_Basis_of

Basis of Presentation Basis of Presentation (Details) (Selling, General and Administrative Expenses, USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015
Selling, General and Administrative Expenses
Prior Period Reclassification Adjustment	$0.50

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Details 2) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Accounting Policies [Abstract]
Income Tax Expense (Benefit)	$0	$0
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	8,918,550	8,306,770

Inventory_Details

Inventory (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]
Raw materials	$355	$357
Work in process	189	214
Inventory	$544	$571

Warrants_Details

Warrants (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Warrants
Warrants issued to purchase common stock	6,033,050	6,033,050
Issued in Series A, B and D Preferred Stock offerings
Warrants
Warrants issued to purchase common stock	2,247,118	2,247,118
Warrant Exercise Price (in dollars per share)	6.25
Issued in March 2010 financing
Warrants
Warrants issued to purchase common stock	393,416	393,416
Warrant Exercise Price (in dollars per share)	6.25
Issued in June 2011 financing
Warrants
Warrants issued to purchase common stock	6,113	6,113
Warrant Exercise Price (in dollars per share)	22.5
Issued in August 2011 financing
Warrants
Warrants issued to purchase common stock	565,759	565,759
Warrant Exercise Price (in dollars per share)	18.75
Issued to placement agents in August 2011 financing
Warrants
Warrants issued to purchase common stock	50,123	50,123
Warrant Exercise Price (in dollars per share)	13.635
Issued in Series B, D and E Preferred Stock offerings
Warrants
Warrants issued to purchase common stock	76,120	76,120
Warrant Exercise Price (in dollars per share)	2.5
Issued with Convertible Notes
Warrants
Warrants issued to purchase common stock	1,125,578	1,125,578
Warrant Exercise Price (in dollars per share)	2.5
Issued in Series E Preferred Stock offering
Warrants
Warrants issued to purchase common stock	1,568,823	1,568,823
Warrant Exercise Price (in dollars per share)	7.5

Warrants_Details_2

Warrants (Details 2) (Warrant Liability, USD $)	3 Months Ended	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Warrant Liability
Fair value assumptions
Warrant liability	$12,949	$11,286
Investment Warrants, Exercise Price	$7.08	$7.08
Closing Price Per Share Of Common Stock	$4.51	$2.59
Volatility (as a percent)	78.50%	67.60%
Weighted average remaining expected life	2 years 4 months	2 years 7 months
Interest rate (as a percent)	0.63%	0.86%
Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%

Warrants_Narrative_Details

Warrants Narrative (Details) (USD $)	3 Months Ended
In Millions, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Exercise of Warrants	0
Cancellation Of Warrants	0
Warrant | Significant unobservable inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Adjustment of Warrants	$1.70	$3.10

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Liabilities
Amount transferred from Level 1 to Level 2	$0	$0
Amount transferred from Level 2 to Level 1	0	0
Amount transferred from Level 1 to Level 2	0	0
Amount transferred from Level 2 to Level 1	0	0
Amount transferred into Level 3	0	0
Amount transferred out of Level 3	0	0
Amount transferred into Level 3	0	0
Amount transferred out of Level 3	0	0
Recurring | Measured at fair value
Assets
Cash and cash equivalents	33,301,000	37,495,000
Liabilities
Warrant liability	12,949,000	11,286,000
Recurring | Measured at fair value | Quoted prices in active markets (Level 1)
Assets
Cash and cash equivalents	33,301,000	37,495,000
Recurring | Measured at fair value | Significant unobservable inputs (Level 3)
Liabilities
Warrant liability	$12,949,000	$11,286,000

Fair_Value_Measurements_Detail1

Fair Value Measurements (Details 2) (Warrant, USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015
Warrant
Fair value measurements
31-Dec-14	$11,286
Change in fair value of warrant liability	1,663
31-Mar-15	$12,949

ShareBased_Compensation_Detail

Share-Based Compensation (Details)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Equity-based compensation
Options issued (in shares)	2,885,500	2,086,450
The Plan
Equity-based compensation
Number of shares allowed for issuance	5,600,000
The Plan | Options
Equity-based compensation
Vesting percentage per year	25.00%
Vesting period	4 years
Options available for grant (in shares)	2,700,253
The Plan | Options | Maximum
Equity-based compensation
Terms of options	10 years
Equity incentive outside of the Plan | Options
Equity-based compensation
Options issued (in shares)	206,000

ShareBased_Compensation_Detail1

Share-Based Compensation (Details 2) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Equity-based compensation
Stock-based compensation expense	$240	$303
Options | Equity awards for nonemployees issued for services
Equity-based compensation
Stock-based compensation expense		3
Options | Employees and directors
Equity-based compensation
Stock-based compensation expense	$240	$300

ShareBased_Compensation_Detail2

Share-Based Compensation (Details 3) (USD $)	3 Months Ended	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2013	Dec. 31, 2014
Number of shares
Outstanding at beginning of period (in shares)	2,086,450
Granted (in shares)	830,300
Exercised (shares)	-31,250
Forfeited (in shares)	0
Expired (in shares)	0
Outstanding at end of period (in shares)	2,885,500
Exercisable at end of period (in shares)	1,162,250
Weighted-average exercise price
Outstanding at beginning of period (in dollars per share)	$7.43
Granted (in dollars per share)	$4.13
Exercised (in dollars per share)	$4.86
Forfeited (in dollars per share)	$0
Expired (in dollars per share)	$0
Outstanding at end of period (in dollars per share)	$6.51
Exercisable at end of period (in dollars per share)	$10.25
Additional disclosures
Weighted-average remaining contractual term (in years), Outstanding	8 years 4 months	8 years 0 months
Weighted-average remaining contractual term (in years), Exercisable	7 years 3 months
Aggregate intrinsic value, Outstanding	$1,510		$0
Aggregate intrinsic value, Exercisable	$349

ShareBased_Compensation_Detail3

Share-Based Compensation (Details 4) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Equity-based compensation
Fair value of shares vested	$200,000
Fair market value of options granted (in dollars per share)	$3.39	$2.88
Weighted average assumptions
Expected life (years)	6 years 2 months	6 years 3 months
Interest rate	1.48%	1.99%
Volatility	106.30%	71.00%
Time-based stock options
Equity-based compensation
Total unrecognized compensation cost	4,100,000
Weighted-average period to recognize compensation cost	3 years 3 months 4 days
Performance based options | Equity awards for nonemployees issued for services
Equity-based compensation
Total unrecognized compensation cost	$0

Collaboration_Agreement_with_R

Collaboration Agreement with Related Party (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Number of directors	7
NRM VII Holdings I, LLC
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Number of directors that are affiliates of related party	2
Intrexon Corporation
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Expenses for work performed	$1.70	$1.10
Outstanding trade payables	$1.90		$1